Purpose and goal:
Urinary bladder cancer patients whose cancer has invaded the muscle layer around the bladder is treated with cisplatin combination drugs prior to operation. Many patients, however, do not respond to these drugs and these patients have reduced survival compared to responders or patients operated immediately after diagnosis. The goal of this Project is to develop a new method for identifying cisplatin non-responders immediately after diagnosis, which can then proceed directly to surgery instead of going through a period of ineffective treatment.
Expected results and effects:
We expect to successfully develop bladder tissue biopsy treatment and implantation methods in zebrafish embryos and in this environment evaluate cisplatin efficacy. The project is designed to evaluate 1) the proportion of patients in which we successfully implant tumor biopsies in zebrafish, 2) which effect of cisplatin observed in the zebrafish models correspond to a clinically meaningful effect in the patients and 3) the proportion of patients in which we correctly predict cisplatin response using the zebrafish model.
Approach and implementation:
Through our Clinical collaborators we expect to recruit 40 urinary bladder cancer patients from Swedish Urology clinics. We will recieve fresh tumor biopsies from these patients during the so-called TUR-B procedure and these biopsies are then pre-treated, labeled and implanted in zebrafish embryos. The tumor baring fish are then treated with two different cisplatin-containing combination drugs (GC or MVAC), alternatively only vehicle (control group), tumor growth or reduction is meassured during a three day treatment period and compared with patient responses